Skip to content
lifestyle.successfuldaily.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Santhera Pharmaceuticals Holding AG
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
June 2, 2026
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
May 26, 2026
Santhera Publishes Agenda for its Annual General Meeting
May 22, 2026
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
May 20, 2026
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
May 20, 2026
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
May 20, 2026
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
May 20, 2026
Santhera Appoints Orlando Oliveira as Chief Executive Officer
May 19, 2026
Full Year 2025 Trading Update
March 12, 2026
1
2
Next Page
→